000			01499 a2200433 4500
005			20250516044203.0
264		0	_c20111222
008			201112s 0 0 ger d
022			_a1433-0563
024	7		_a10.1007/s00120-011-2545-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aSchmedders, M
245	0	0	_a[Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer]. _h[electronic resource]
260			_bDer Urologe. Ausg. A _cAug 2011
300			_a938-43 p. _bdigital
500			_aPublication Type: English Abstract; Journal Article
650	0	4	_aAged
650	0	4	_aBrachytherapy _xeconomics
650	0	4	_aCost-Benefit Analysis
650	0	4	_aEvidence-Based Medicine _xeconomics
650	0	4	_aGermany
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNational Health Programs _xeconomics
650	0	4	_aNeoplasm Staging
650	0	4	_aProstatectomy _xeconomics
650	0	4	_aProstatic Neoplasms _xeconomics
650	0	4	_aQuality Assurance, Health Care _xeconomics
650	0	4	_aRadioisotope Teletherapy _xeconomics
650	0	4	_aRadiotherapy Dosage
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRisk Factors
650	0	4	_aSurvival Rate
700	1		_aJanatzek, S
700	1		_aZimmer, B
773	0		_tDer Urologe. Ausg. A _gvol. 50 _gno. 8 _gp. 938-43
856	4	0	_uhttps://doi.org/10.1007/s00120-011-2545-3 _zAvailable from publisher's website
999			_c20973756 _d20973756